{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:12:19Z","timestamp":1788894739215,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of disitamab vedotin (RC48) in the treatment of advanced gastric cancer in real-world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on clinical data of patients with human epidermal growth factor receptor 2 (HER2)-expressing advanced gastric cancer who were treated with disitamab vedotin at our institution between October 2021 and October 2024. Clinical efficacy and adverse events were assessed. Factors influencing the efficacy of disitamab vedotin were evaluated using the Log-rank test for intergroup analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 58 patients with HER2-expressing advanced gastric cancer who received RC48 treatment were included in this study. The objective response rate (ORR) was 10.3%, and the disease control rate (DCR) was 63.8%. The median progression-free survival (mPFS) for all patients was 4.2 months (95% CI\u00a0=\u00a03.002-5.398), with a 1-year progression-free survival rate of 13.0%. Subgroup analysis revealed that DCR was significantly higher in patients receiving RC48 as third-line therapy compared to those receiving it as later-line therapy (75.0%\n                      <jats:italic>vs<\/jats:italic>\n                      . 50.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.049). The DCR was also significantly higher in patients who experienced adverse drug reactions (ADRs) than in those who did not (76.7%\n                      <jats:italic>vs<\/jats:italic>\n                      . 50.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.035). Male patients had a significantly longer mPFS than female patients (4.9 months\n                      <jats:italic>vs.<\/jats:italic>\n                      2.6 months, Log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.006). Common RC48-related ADRs included neutropenia, hemoglobin reduction, and liver impairment. The incidence of grade III or higher ADRs was 17.2% (10\/58). Univariate analysis indicated that the presence of underlying diseases and the line of RC48 therapy were significantly associated with the occurrence of ADRs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the real-world setting, RC48 shows some clinical efficacy and a manageable safety profile in patients with HER2-expressing advanced gastric cancer. These findings provide useful information for clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1807824","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:48:30Z","timestamp":1779252510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world"],"prefix":"10.3389","volume":"16","author":[{"given":"Pan","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jingjiang People\u2019s Hospital Affiliatedo Yangzhou University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjuan","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Tumor Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangjia","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital\/The Affiliated Cancer Hospital of Nanjing Medical University\/Jiangsu Institute of Cancer Research","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Puer People\u2019s Hospital","place":["Puer, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shining","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Ditan Hospital Affiliated to Capital Medical University Xuzhou Hospital (Xuzhou Seventh People\u2019s Hospital)","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhoukou First People\u2019s Hospital","place":["Zhoukou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshi","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Tumor Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jingjiang People\u2019s Hospital Affiliatedo Yangzhou University","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liu","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital\/The Affiliated Cancer Hospital of Nanjing Medical University\/Jiangsu Institute of Cancer Research","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.12354\/j.issn.1000-8179.2024.20241401","article-title":"Chinese expert consensus on anti-HER2 therapy for gastric cancer (2024 edition)","volume":"51","author":"Liang","year":"2024","journal-title":"Chin J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1080990","article-title":"Challenges and future of HER2-positive gastric cancer therapy","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41392-024-01932-y","article-title":"Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103679","article-title":"HER2-low gastric cancer: is the subgroup targetable","volume":"9","author":"Shimozaki","year":"2024","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.11735\/j.issn.1671-170X.2025.05.B008","article-title":"Efficacy and safety of Disitamab Vedotin in patients with HER2-positive metastatic breast cancer","volume":"31","author":"Zhang","year":"2025","journal-title":"J Chin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.757994","article-title":"From AVATAR mice to patients: RC48-ADC exerted promising efficacy in advanced gastric cancer with HER2 expression","volume":"12","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B10","article-title":"Guidelines for diagnosis and treatment of gastric cancer","volume-title":"People\u2019s medical publishing house","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092538","article-title":"Steroid-refractory immune-related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3872\/j.issn.1007-385x.2023.11.013","article-title":"Advances in research and development of molecular targeted drugs for advanced gastric cancer","volume":"30","author":"Wu","year":"2023","journal-title":"Chin J Cancer Biother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumors: a multicenter, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-5725.2024.20.015","article-title":"Clinical efficacy and safety of disitamab vedotin in the treatment of advanced gastric cancer","volume":"40","author":"Xu","year":"2024","journal-title":"J Pract Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147468","article-title":"Enhancing vulnerability of Afatinib using Erastin via xCT-mediated ROS\/P38MAPK signaling feedback loop in gastric cancer cells","volume":"873","author":"Wei","year":"2023","journal-title":"Gene"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B19","article-title":"Exploring the role and mechanism of ERB based on SRSF2 in the gender difference of anti-PD-1\/PD-L1 immunotherapy for lung adenocarcinoma","author":"Dai","year":"2024"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1807824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:48:42Z","timestamp":1779252522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1807824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":19,"alternative-id":["10.3389\/fonc.2026.1807824"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1807824","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1807824"}}